A phase II, randomized trial using the small molecule tyrosine kinase inhibitor lapatinib as a first-line treatment in patients with FISH positive advanced or metastatic breast cancer
Henry Gómez(National Cancer Center), G. W. Sledge(Stanford Medicine), Brian Wood(GlaxoSmithKline (India)), M. S. Berger(Duke University), Louis WC Chow(Unimed Medical Institute), Dinesh Chandra Doval(Rajiv Gandhi Cancer Institute and Research Centre), Miguel A. Chavez(GlaxoSmithKline (India))
Cited by 72
Related Papers
5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)
|Annals of Oncology|2020|1.4k
4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)
|Annals of Oncology|2018|1.2k
Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast Cancer
|New England Journal of Medicine|2014|751
Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer
|New England Journal of Medicine|2018|684